Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): (Formula (I)); where R1, and R2 are as described herein.

Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R4, R4a, R7, R7a, and X2 are as described herein.

Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified, non-hydrated ketone saxitoxins.

Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R4, R4a, R7, R7a, and X2 are as described herein.

Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R1, X1, and X2 are as described herein.

Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R4, R4a, R7, R7a, and X2 are as described herein.

Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): (Formula (I)); where R1, and R2 are as described herein.

Abstract: A method of generating a control signal for a temperature control system is disclosed. The control signal has one of an “on” state in which the temperature control system is to be activated and an “off” state in which the temperature control system is to be deactivated. The method comprises calculating a temperature error measure in dependence on a target temperature and a current temperature value. A rate of temperature change in the environment is determined and used to set a variable error threshold. The method switches between a continuous “on” signal mode and a pulse-width-modulation (PWM) mode, in which the output signal comprises alternating “off” and “on” periods in accordance with a PWM pattern. The switch occurs in dependence on the temperature error measure and the variable error threshold.

Abstract: There is disclosed an interactive patient care system configured to provide care to a patient suffering from a chronic disease or condition, comprising a server system (6) configured to receive and transmit data via a communication network (16) to and from users including 5 patients (15a) and health care professionals (15b). The server system comprises a processing unit (6e), a memory (6f), a patient database (6c) configured to store data related to the patient and a library database (6d) configured to store data related to predefined therapeutic interventions obtained on evidence-based care pathways. The server system further comprises an application server (6b) and a communication server (6a) including a web server 10 software application for data transfer through the internet.

Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R1, X1, and X2 are as described herein.

Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R4, R4a, R7, R7a, and X2 are as described herein.

Abstract: Saxitoxin analogue compounds, compositions, pharmaceutical compositions, methods of synthesis of saxitoxin analogues, methods of imaging, methods of treatment, including methods of treating pain, are provided. Saxitoxin (STX), gonyautoxin (GTX), and zetekitoxin, and variant STX compounds bind to sodium channels and are effective to reduce or block flow of sodium ions through such channels. Such channel block affects nerve and muscle action, and may be effective to reduce or block pain sensations, relax muscles, reduce muscle spasm, and reduce wrinkles. STX analogue binding to sodium channels may also be useful to locate, image, or mark sodium channels, and so be useful in studying sodium channels and sodium channel disorders, and in the diagnosis and treatment of patients suffering from sodium channel disorders. In embodiments, the variant STX compounds include conjugates having increased serum half-life as compared to STX when administered to a subject.

Abstract: A method of generating a control signal for a temperature control system is disclosed. The control signal has one of an “on” state in which the temperature control system is to be activated and an “off” state in which the temperature control system is to be deactivated. The method comprises calculating a temperature error measure in dependence on a target temperature and a current temperature value. A rate of temperature change in the environment is determined and used to set a variable error threshold. The method switches between a continuous “on” signal mode and a pulse-width-modulation (PWM) mode, in which the output signal comprises alternating “off” and “on” periods in accordance with a PWM pattern. The switch occurs in dependence on the temperature error measure and the variable error threshold.

Abstract: A battery-powered environmental control and/or sensor device is disclosed. The device includes a mounting plate arranged to be affixed to a support surface; and a main body including a battery compartment. The main body is adapted to be releasably secured to the mounting plate, with the battery compartment being substantially inaccessible when the main body is secured to the mounting plate. The mounting plate and main body comprise complementary securing elements arranged to secure the main body to the mounting plate. The mounting plate or the main body include a lever having a portion extending beyond a periphery of the device so as to be operable by a device user when the main body is secured to the mounting plate. The lever is operable when activated to disengage the complementary securing elements and separate the main body from the mounting plate to provide access to the battery compartment.

Abstract: Patient care system comprising a medical device (1) for administering a medical treatment to a patient (15a) and a server system (6) configured to receive and transmit data via a communications network (16) to, respectively from users including patients (15a) and health care professionals (15b), the server system further configured to process and store data related to patient care.

Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R1, X1 and X3 are as described herein.

Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function, for example conditions associated with pain. The compounds are 10?,11?-modified saxitoxins. The compounds are optionally additionally modified at carbon 13. In certain embodiments, the 10?,11?-modified saxitoxins are of Formula I: where R1, R2 and R3 are as described herein. Also provided herein are methods of treating pain in a mammal comprising administering an effective treatment amount of a 10?,11? modified saxitoxin or composition to a mammal. In an embodiment, the mammal is a human.

Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R1, X1 and X3 are as described herein.

Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function, for example conditions associated with pain. The compounds are 10?,11?-modified saxitoxins. The compounds are optionally additionally modified at carbon 13. In certain embodiments, the 10?,11?-modified saxitoxins are of Formula I: where R1, R2 and R3 are as described herein. Also provided herein are methods of treating pain in a mammal comprising administering an effective treatment amount of a 10?,11? modified saxitoxin or composition to a mammal. In an embodiment, the mammal is a human.

Abstract: A battery-powered environmental control and/or sensor device is disclosed. The device includes a mounting plate arranged to be affixed to a support surface; and a main body including a battery compartment. The main body is adapted to be releasably secured to the mounting plate, with the battery compartment being substantially inaccessible when the main body is secured to the mounting plate. The mounting plate and main body comprise complementary securing elements arranged to secure the main body to the mounting plate. The mounting plate or the main body include a lever having a portion extending beyond a periphery of the device so as to be operable by a device user when the main body is secured to the mounting plate. The lever is operable when activated to disengage the complementary securing elements and separate the main body from the mounting plate to provide access to the battery compartment.